I agree that a 20% royalty would be a good outcome for a P1 drug.
But bisantrene has been given to 1,500 patients and has been approved once by a regulator.
I'm not saying anything about whether the cost to get there is reasonable or not.
I'm just saying that there will have to be bonus options attached to the CR.
Competition: Guess the strike price of the sweetener options, page-6
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.60 |
Change
-0.130(7.51%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.74 | $1.60 | $313.3K | 191.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8179 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |